AtriCure (ATRC) Q3 2026 Earnings Call Transcript

AtriCure reported Q3 2026 revenue of $154.5 million, up 15% year over year, and net income of $4.1 million versus a $0.3 million loss a year earlier; adjusted EBITDA rose 50.6% to $26.8 million. The company raised full-year adjusted EBITDA guidance to $91 million–$94 million and expects revenue of $606 million–$610 million, while citing international funding challenges and continued pressure in minimally invasive ablation. BoxX-NoAF enrollment exceeded 880 patients, and FDA-cleared 30-millimeter AtriClip FLEX-Mini sales are expected to launch in December 2026.

Analysis

The operating leverage is real, but its durability is less proven than the headline EBITDA growth suggests: quarterly gross margin benefited from favorable U.S./product mix, while management expects a near-term step-down as the new facility’s costs flow through. At the same time, planned clinical and commercial investment can absorb some incremental gross profit. Watch adjusted EBITDA conversion and gross margin together rather than extrapolating this quarter’s earnings cadence.

The strongest near-term mechanism is more procedures per established account, not simply adding accounts. That supports revenue visibility, but also makes adoption intensity and surgeon workflow the key limits to growth. Open ablation’s concentration in EnCompass raises execution/product-dependence risk; minimally invasive ablation remains exposed to substitution by PFA catheter therapy. The STS metric is an adoption tailwind, not a January 2027 step-change: a phased rollout makes the ramp multi-year. Likewise, BoxX-NoAF enrollment completion is not efficacy evidence. Spring 2027 data are the consequential catalyst, with regulatory and commercial effects later and contingent on results.

Contrarian read: the prudent year-end outlook may understate U.S. demand, but the international funding weakness and U.S. hybrid softness are explicitly persistent, not just quarterly noise. Do not capitalize cryoXT as a material earnings driver yet; current contribution is small relative to the franchise, with broader uptake a 2027–28 possibility.

Key Decisions for Investors

• Construct a staged long ATRC position on post-earnings volatility rather than chasing strength; the thesis is U.S. procedure adoption plus multi-year STS support. Reassess after spring 2027 BoxX-NoAF data. No price target without valuation and post-call trading data.
• For the next 1–3 quarters, track U.S. open ablation and pain growth alongside gross margin and adjusted EBITDA: a margin decline with sustained U.S. growth may be mix/facility normalization, but simultaneous growth deceleration and margin compression would invalidate the operating-leverage thesis.
• Treat BoxX-NoAF as a binary catalyst, not a booked growth asset: reduce exposure if the spring 2027 primary-endpoint data disappoint or enrollment/readout timing slips materially; positive data would improve the case for later adoption, but FDA timing and uptake remain separate hurdles.
• Avoid assuming a rapid international rebound or near-term recovery in minimally invasive ablation. Falsifiers for the cautious view would be renewed international acceleration and stabilization of that segment; monitor reported franchise trends and any guidance revision.